Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Imatinib has revolutionised the treatment of chronic myeloid leukaemia (CML). The first
clinical trials were conducted in 1998 in patients with advanced disease, and by 2002
imatinib was established as the standard therapy for all patients including those recently
diagnosed. In spite of overwhelming evidence about its efficacy we still need to gain more
knowledge about issues related to long term treatment with imatinib such as why some patients
respond better than others, the development of side effects and the quality of life.